Stockscreener 앱 받기
437.33
0.30%
-1.33
시간 외 거래:
439.00
1.67
+0.38%
전일 마감가:
$438.66
열려 있는:
$432.75
하루 거래량:
618.31K
Relative Volume:
0.81
시가총액:
$19.73B
수익:
$3.08B
순이익/손실:
$1.24B
주가수익비율:
17.08
EPS:
25.6108
순현금흐름:
$1.07B
1주 성능:
+5.29%
1개월 성능:
-3.47%
6개월 성능:
+48.45%
1년 성능:
+16.06%
1일 변동 폭
$430.02
$440.00
1주일 범위
$415.26
$479.50
52주 변동 폭
$266.98
$479.50
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Access Investment Management LLC Makes New $2.14 Million Investment in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation $UTHR Position Lessened by Bessemer Group Inc. - MarketBeat
Combining machine learning predictions for United Therapeutics CorporationMarket Performance Recap & Verified Technical Trade Signals - newser.com
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease - The Joplin Globe
United Therapeutics (Nasdaq: UTHR) starts EXPAND with first UKidney xenotransplant - Stock Titan
Can technical indicators confirm United Therapeutics Corporation’s reversalWeekly Stock Report & High Accuracy Swing Trade Signals - newser.com
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock - MarketBeat
United Therapeutics Hits Day High with 9.63% Surge in Stock Price - Markets Mojo
Is United Therapeutics Corporation (UTH) stock a top dividend aristocrat candidateRisk Management & Reliable Entry Point Trade Alerts - newser.com
MSN Money - MSN
United Therapeutics Corp. Hits New 52-Week High of $479.50 - Markets Mojo
United Therapeutics posts record revenue but misses Q3 earnings expectations - MSN
Focus Partners Advisor Solutions LLC Buys Shares of 1,440 United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation - MSN
United Therapeutics CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
3rd Circ. Preview: BMW, MiLB And Sandoz Top Nov. Lineup - Law360
United Therapeutics (NASDAQ:UTHR) Given New $423.00 Price Target at Wells Fargo & Company - MarketBeat
Assetmark Inc. Boosts Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Will United Therapeutics Corporation stock benefit from upcoming earnings reportsOptions Play & Technical Pattern Alert System - newser.com
United Therapeutics Executives Sell Shares - TradingView
United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Wells Fargo Maintains United Therapeutics (UTHR) Equal-Weight Recommendation - Nasdaq
United Therapeutics (NASDAQ:UTHR) Reaches New 12-Month High After Better-Than-Expected Earnings - MarketBeat
United Therapeutics price target raised to $587 from $569 at RBC Capital - TipRanks
United Therapeutics price target raised to $447 from $435 at Morgan Stanley - TipRanks
United Therapeutics (UTHR) Earnings Transcript - AOL.com
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2025 Earnings Call Transcript - Insider Monkey
United Therapeutics’ AI-Driven Study: A Potential Game-Changer for Pulmonary Hypertension Diagnosis - MSN
United Therapeutics’ PHINDER Study: A Step Forward in Early Detection of Pulmonary Hypertension - MSN
Silver Spring-based United Therapeutics reports Q3 earnings - Maryland Daily Record
Published on: 2025-10-31 23:58:52 - newser.com
United Therapeutics Reports Record Q3 2025 Results - TipRanks
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus
United Therapeutics: Q3 Earnings Snapshot - CT Insider
United Therapeutics (NASDAQ:UTHR) COO Sells $9,393,750.00 in Stock - MarketBeat
Why Is United Therapeutics (UTHR) Stock Soaring Today - Yahoo Finance
United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark - TradingView
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday - Benzinga
United Therapeutics Q3 2025 Earnings ReportRevenue & Profit AnalysisNews and Statistics - IndexBox
United Therapeutics Q3 2025 Earnings: Profit Beats ForecastsNews and Statistics - IndexBox
United Therapeutics (UTHR) Beats Q3 Earnings Estimates - Yahoo Finance
United Therapeutics Grows Revenue, But Misses Earnings Forecast - Finimize
United Therapeutics Corp Q3 2025 Earnings: EPS of $7.16 Beats Es - GuruFocus
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings - Yahoo Finance
United Therapeutics Corp Announces Rise In Q3 Bottom Line - Nasdaq
United Therapeutics misses Q3 expectations despite record revenue - Investing.com
United Therapeutics misses Q3 expectations despite record revenue By Investing.com - Investing.com Philippines
United Therapeutics Q3 revenue misses estimates - TradingView
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results - TradingView
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.87%
자본화:
|
볼륨(24시간):